131 related articles for article (PubMed ID: 28235246)
1. Assessing cervical intraepithelial neoplasia as an indicator disease for HIV in a low endemic setting: a population-based register study.
Carlander C; Marrone G; Brännström J; Yilmaz A; Elfgren K; Sparén P; Sönnerborg A
BJOG; 2017 Oct; 124(11):1680-1687. PubMed ID: 28235246
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden.
Carlander C; Wagner P; Svedhem V; Elfgren K; Westling K; Sönnerborg A; Sparén P
Int J Cancer; 2016 Oct; 139(7):1471-9. PubMed ID: 27177207
[TBL] [Abstract][Full Text] [Related]
4. Minimally abnormal Pap testing and cervical histology in HIV-infected women.
Curry CL; Sage YH; Vragovic O; Stier EA
J Womens Health (Larchmt); 2012 Jan; 21(1):87-91. PubMed ID: 22011239
[TBL] [Abstract][Full Text] [Related]
5. Persistence and clearance of high-risk human papillomavirus and cervical dysplasia at 1 year in women living with human immunodeficiency virus: a prospective cohort study.
Luckett R; Painter H; Hacker MR; Simon B; Seiphetlheng A; Erlinger A; Eakin C; Moyo S; Kyokunda LT; Esselen K; Feldman S; Morroni C; Ramogola-Masire D
BJOG; 2021 Nov; 128(12):1986-1996. PubMed ID: 34008294
[TBL] [Abstract][Full Text] [Related]
6. Screening capacity and cost-effectiveness of the human papillomavirus test versus cervicography as an adjunctive test to Pap cytology to detect high-grade cervical dysplasia.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():112-116. PubMed ID: 30682600
[TBL] [Abstract][Full Text] [Related]
7. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
8. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.
Lamin H; Eklund C; Elfström KM; Carlsten-Thor A; Hortlund M; Elfgren K; Törnberg S; Dillner J
BMJ Open; 2017 May; 7(5):e014788. PubMed ID: 28566363
[TBL] [Abstract][Full Text] [Related]
9. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
[TBL] [Abstract][Full Text] [Related]
10. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
[TBL] [Abstract][Full Text] [Related]
11. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
[TBL] [Abstract][Full Text] [Related]
13. Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: Characteristics of the responders.
Gök M; Heideman DA; van Kemenade FJ; de Vries AL; Berkhof J; Rozendaal L; Beliën JA; Overbeek L; Babović M; Snijders PJ; Meijer CJ
Eur J Cancer; 2012 Aug; 48(12):1799-808. PubMed ID: 22172570
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of human papillomavirus (HPV) 16 and HPV18 viral loads for the detection of high-grade cervical intraepithelial neoplasia (CIN2+) in a cohort of African women living with HIV.
Segondy M; Ngou J; Kelly H; Omar T; Goumbri-Lompo O; Doutre S; Mayaud P; Didelot MN
J Clin Virol; 2018; 99-100():79-83. PubMed ID: 29353074
[TBL] [Abstract][Full Text] [Related]
15. Screening of cervical neoplasia in HIV-infected women in India.
Joshi S; Sankaranarayanan R; Muwonge R; Kulkarni V; Somanathan T; Divate U
AIDS; 2013 Feb; 27(4):607-15. PubMed ID: 23079814
[TBL] [Abstract][Full Text] [Related]
16. A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study.
Zorzi M; Frayle H; Rizzi M; Fedato C; Rugge M; Penon MG; Bertazzo A; Callegaro S; Campagnolo M; Ortu F; Del Mistro A;
BJOG; 2017 Sep; 124(10):1585-1593. PubMed ID: 28120382
[TBL] [Abstract][Full Text] [Related]
17. HPV prevalence and cervical intraepithelial neoplasia among HIV-infected women in Yunnan Province, China: a pilot study.
Zhang HY; Tiggelaar SM; Sahasrabuddhe VV; Smith JS; Jiang CQ; Mei RB; Wang XG; Li ZA; Qiao YL
Asian Pac J Cancer Prev; 2012; 13(1):91-6. PubMed ID: 22502720
[TBL] [Abstract][Full Text] [Related]
18. Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women-A cohort study.
Westre B; Giske A; Guttormsen H; Wergeland Sørbye S; Skjeldestad FE
PLoS One; 2019; 14(11):e0221546. PubMed ID: 31689301
[TBL] [Abstract][Full Text] [Related]
19. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.
Bulk S; Bulkmans NW; Berkhof J; Rozendaal L; Boeke AJ; Verheijen RH; Snijders PJ; Meijer CJ
Int J Cancer; 2007 Jul; 121(2):361-7. PubMed ID: 17354241
[TBL] [Abstract][Full Text] [Related]
20. Performance of alternative strategies for primary cervical cancer screening in sub-Saharan Africa: systematic review and meta-analysis of diagnostic test accuracy studies.
Fokom-Domgue J; Combescure C; Fokom-Defo V; Tebeu PM; Vassilakos P; Kengne AP; Petignat P
BMJ; 2015 Jul; 351():h3084. PubMed ID: 26142020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
